Guangzhou, China --(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, announced today the details of its poster presentation at the Vaccines Summit 2022, being held from October 11-13 in Washington D.C. Bio-Thera will present research and preclinical results of a highly thermal stable recombinant bivalent nanoparticle vaccine containing spikes of SARS-CoV-2 Omicron and Delta, showing high immunogenicity and potentially offering broad cross-protection against ever evolving Covid-19 variants.
Preclinical studies showed that the candidate vaccine was highly immunogenic in both mice and rats, could elicit robust broadly cross-reactive neutralizing antibodies against all major SARS-Cov-2 variants. The candidate vaccine protected all the K18-hACE2 transgenic mice challenged with lethal dose of Omicron variant from body weight loss and death, with undetectable live virus in their lung tissues. This vaccine candidate leverages the self-assembled stable nanoparticles, is formulated with Bio-Thera’s proprietary formulation platform, and is highly stable across a broad range of temperature from freezing to over 40-degree Celsius. This vaccine candidate thus could be a valuable strategy for vaccination against the ever-changing SARS-CoV-2, especially for the remote and low-income regions in the globe.
Details of the presentation are as follows:
Presentation Title: Highly Thermal Stable Recombinant Bivalent Nanoparticle Vaccine Containing Spikes of SARS-CoV-2 Omicron and Delta Shows High Immunogenicity and Potentially Offers Broad Cross-Protection
Session Title: Poster presentation session
Session Date and Time: Tuesday, October 11, from 6:00 PM – 7:00 PM EST
Location: Sheraton Reston Hotel, 11810 Sunrise Valley Dr, Reston, VA 20191 at Foyer area
Poster Board Number: P-011
About Bio-Thera Solutions
Bio-Thera Solutions, Ltd., a leading global biotechnology company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. A leader in next generation antibody discovery and engineering, the company has advanced six candidates into late-stage clinical trials and has two approved products, QLETLI? and POBEVCY? in China. In addition, the company has multiple promising candidates in early clinical trials and IND-enabling studies, focusing on immuno-oncology, ADC targeted therapies, autoimmune diseases, and other severe and emerging unmet medical needs. For more information, please visit www.helizi.cn/en/ or follow us on Twitter (@bio_thera_sol) and WeChat (Bio-Thera).
Cautionary Note Regarding Forward-Looking Statements
This news release contains certain forward-looking statements relating to the aforementioned vaccine candidate or the product pipelines in general of Bio-Thera Solutions. Readers are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. The forward-looking statements include, among others, those containing “could,” “may,” “should,” “will,” “would,” “anticipate,” “believe,” “plan,” “promising,” “potentially,” or similar expressions. They reflect the company’s current views with respect to future events that are based on what the company believes are reasonable assumptions in view of information currently available to Bio-Thera Solutions, and are not a guarantee of future performance or developments. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, but not limited to, risks and uncertainties inherent in pharmaceutical research and development, such as the uncertainties of pre-clinical and clinical studies, for example, the development processes could be lengthy and high in vitro affinity may not translate to desired results in vivo or successful clinical studies. Other risks and uncertainties include challenges in obtaining regulatory approvals, manufacturing, marketing, competition, intellectual property, product efficacy or safety, changes in global healthcare situation, changes in the company’s financial conditions, and changes to applicable laws and regulations, etc. Forward-looking statements contained herein are made only as of the date of their initial publication. Unless required by laws or regulations, Bio-Thera Solutions undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, changes in the company’s views or otherwise.
